Specifically, UBE2F upregulation enhances the neddylation levels and CUL5 activity, thereby reinforcing CRL5-mediated degradation of NOXA and leading to platinum and etoposide resistance in non-small cell lung cancer (NSCLC) and CRC [36, 64]. The gene discussed is UBE2F; the disease is non-small cell lung carcinoma.